Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Real-world validation of ELN2024 and BEAT-AML2024 risk-stratification in patients with Acute Myeloid Leukemia unfit for intensive chemotherapy in a multicenter italian cohort.

View Full Paper
Ask AI
Bookmark
Share

Authors

ETElisabetta TodiscoESEnrico SantinelliCPCristina Papayannidis

Discussion

Loading...

Member takes

Overview

Observational analysis assessed overall survival in unfit AML patients, indicating BEAT-AML2024 excels in risk stratification.

Key Points

  • Median overall survival was 14 months for patients treated with hypomethylating agents and venetoclax in this cohort.
  • Among 171 patients, BEAT-AML2024 demonstrated superior predictive performance with a C-index of 0.603 compared to others.
  • Genetic alterations and molecular analysis informed risk stratification across various treatment modalities for AML.
  • The findings suggest that BEAT-AML2024 more effectively evaluates survival and treatment implications than ELN2024.

Cite This Study

Todisco et al. (2025) studied this question.

synapsesocial.com/papers/69362f7d4fa91c937236e454https://doi.org/10.1182/blood-2025-1624
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Treatment-specific prognostic performance of ELN 2022, ELN 2024, and beat AML 2024: A real-world AML validation study2025
  2. 2Risk stratification of newly diagnosed AML receiving nonintensive treatment2025
  3. 3Prognostic evaluation of ELN-2022 and ELN-2024 risk stratification in newly diagnosed AML patients and development of a novel genetic risk model2025
  4. 4Performance of the ELN 2022 risk stratification in a real-world Canadian AML patient population2025
  5. 5Refined genetic risk model with complex karyotype predicts outcomes of newly diagnosed acute myeloid leukemia treated with decitabine plus venetoclax2025